| Literature DB >> 24759619 |
Leonhard Schilbach1, Veronika I Müller2, Felix Hoffstaedter2, Mareike Clos3, Roberto Goya-Maldonado4, Oliver Gruber4, Simon B Eickhoff2.
Abstract
Alterations of social cognition and dysfunctional interpersonal expectations are thought to play an important role in the etiology of depression and have, thus, become a key target of psychotherapeutic interventions. The underlying neurobiology, however, remains elusive. Based upon the idea of a close link between affective and introspective processes relevant for social interactions and alterations thereof in states of depression, we used a meta-analytically informed network analysis to investigate resting-state functional connectivity in an introspective socio-affective (ISA) network in individuals with and without depression. Results of our analysis demonstrate significant differences between the groups with depressed individuals showing hyperconnectivity of the ISA network. These findings demonstrate that neurofunctional alterations exist in individuals with depression in a neural network relevant for introspection and socio-affective processing, which may contribute to the interpersonal difficulties that are linked to depressive symptomatology.Entities:
Mesh:
Year: 2014 PMID: 24759619 PMCID: PMC3997658 DOI: 10.1371/journal.pone.0094973
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Significant results of the ALE meta-analysis delineating the ISA network (A; taken from13) and volumes of interest (VOIs) used for the functional connectivity analysis in healthy controls and patients (B).
ACC: anterior cingulate cortex; AmyL: left Amygdala; dmPFC: dorsomedial prefrontal cortex; PrC: precuneus; SGC: subgenual cingulate cortex.
Activation peaks of ISA network (taken from13).
| Macroanatomical location | MNI coordinates | ||
| x | y | z | |
| Subgenual cingulate cortex (SGC) | 0 | 32 | −12 |
| Anterior cingulate cortex (ACC) | 0 | 36 | 10 |
| Amygdala (AmyL) | −22 | −6 | −24 |
| Precuneus (PrC) | −4 | −54 | 22 |
| Dorsomedial prefrontal cortex (dmPFC) | −2 | 52 | 14 |
Activation peaks of control network (taken from18).
| Macroanatomical location | MNI coordinates | ||
| x | y | z | |
| Middle temporal gyrus (MTG) | −57 | −27 | −5 |
| Inferior frontal gyrus (IFG) | −51 | 20 | 15 |
| Thalamus | −6 | −11 | 5 |
| Angular gyrus (AG) | −48 | −56 | 29 |
Group characteristics. SD: standard deviation; M: male; F: female; BDI: Beck Depression Inventory II, HRSD: Hamilton Rating Scale for Depression.
| Control group | Patient group | |
|
| ||
| Entire group | 57 | 57 |
| Aachen subgroup | 30 | 30 |
| Goettingen subgroup | 27 | 27 |
|
| M: 30; F: 27 | M: 30; F: 27 |
|
| ||
| Entire group | 36.74 (11.48) | 36.89 (11.40) |
| Aachen subgroup | 36.10 (12.58) | 36.10 (12.21) |
| Goettingen subgroup | 37.44 (10.56) | 37.78 (10.82) |
|
| 13.78 (2.93) | 13.81 (3.39) |
|
| 1.33 (2.34) | 20.12 (9.18) |
|
| - | 16.23 (10.07) |
| Aachen subgroup | - | 12.20 (8.15) |
| Goettingen subgroup | - | 20.7 (10.24) |
|
| - | 25.74 (10.36) |
|
| - | 9.09 (9.35) |
|
| - | 3.23 (3.03) |
Medication data for all patients.
| Patient # | Medication - Antidepressants | Medication - Other |
| 1 | Venlafaxine | |
| 2 | Lithium | |
| 3 | Venlafaxine, Lithium | |
| 4 | Citalopram | |
| 5 | Duloxetine | |
| 6 | Citalopram | |
| 7 | Venlafaxine | |
| 8 | Duloxetine | Quetiapine |
| 9 | Opipramol, Sertraline, Mirtazapine | |
| 10 | Venlafaxine, Mirtazapine | |
| 11 | Reboxetine | |
| 12 | Sertraline | |
| 13 | Escitalprame | |
| 14 | Venlafaxine | |
| 15 | Amitriptylinoxid | Topiramate |
| 16 | Quetiapine | |
| 17 | Venlafaxine | |
| 18 | Duloxetine | |
| 19 | Mirtazapine, Citalopram | |
| 20 | Mirtazapine | |
| 21 | Paroxetine | |
| 22 | Citaloprame | |
| 23 | Venlafaxine | |
| 24 | Bupropion | Quetiapine |
| 25 | Sertraline | |
| 26 | Mirtazapine, Venlafaxine | |
| 27 | Citalopram | |
| 28 | Mirtazapine | |
| 29 | Sertraline | |
| 30 | Venlafaxine, Mirtazapine | |
| 31 | Lithium, Escitalopram | Melperone |
| 32 | Venlafaxine, Mirtazapine | Pipamperone, Zopiclone |
| 33 | Escitalopram | Lorazepame |
| 34 | Escitalopram, Mirtazapine | |
| 35 | Duloxetine, Mirtazapine | |
| 36 | Venlafaxine, Mirtazapine | Quetiapine, Lorazepame |
| 37 | ||
| 38 | Citalopram | |
| 39 | Escitaloprame, Agomelatine | Quetiapine, Zopiclone |
| 40 | Escitalopram | |
| 41 | Amitriptyline | Risperidone, Pregabaline |
| 42 | Escitalopram | Quetiapine |
| 43 | Fluoxetine | Quetiapine |
| 44 | Sertraline, Mirtazapine | |
| 45 | ||
| 46 | Venlafaxine, Reboxetine | Valproic acid |
| 47 | Venlafaxine | |
| 48 | ||
| 49 | Escitaloprame, Amitriptyline | |
| 50 | Citalopram | |
| 51 | Amitriptylin | Valproic acid |
| 52 | Venlafaxine, Mirtazapine | Olanzapine |
| 53 | Mirtazapine, Escitaloprame | |
| 54 | ||
| 55 | Mirtazapine, Venlafaxine | |
| 56 | Mirtazapine | |
| 57 | Venlafaxine |
Comparison of motion parameters across groups and sites. SD: standard deviation, DVARS: temporal derivative of timecourses (cf. Power et al. 2012), FD: framewise displacement (cf. van Dijck et al. 2012), RMS: variance over voxels (cf. Satterthwaite et al. 2013).
| Control group | Patient group | Statistical comparison (p-values) | |
|
| |||
| Entire group mean (SD) | 1.37 (0.28) | 1.42 (0.32) | 0.4346/0.4771 |
| Aachen subgroup mean (SD) | 1.19 (0.17) | 1.30 (0.29) | 0.1007/0.2394 |
| Goettingen subgroup mean (SD) | 1.55 (0.26) | 1.52 (0.32) | 0.7022/0.6836 |
|
| |||
| Entire group mean (SD) | 0.28 (0.12) | 0.30 (0.18) | 0.4427/0.7256 |
| Aachen subgroup mean (SD) | 0.25 (0.12) | 0.32 (0.23) | 0.1617/0.1945 |
| Goettingen subgroup mean (SD) | 0.31 (0.12) | 0.28 (0.14) | 0.5233/0.5175 |
|
| |||
| Entire group mean (SD) | 0.20 (0.09) | 0.22 (0.14) | 0.3499/0.6861 |
| Aachen subgroup mean (SD) | 0.18 (0.08) | 0.24 (0.18) | 0.1454/0.1772 |
| Goettingen subgroup mean (SD) | 0.22 (0.08) | 0.21 (0.10) | 0.5961/0.4869 |
Figure 2Results of the resting state functional connectivity analysis in the control and patient group for ISA (left) and control network (right).
Bar plots depict measures of functional connectivity for patients (red) and controls (green) across the two different measurement sites (light colors: Aachen; dark colors: Goettingen).
Figure 3Significant results of the comparison of functional connectivity between patient subgroups of short and long disease duration and early and late onset of illness.
Subgroups were defined each by a median split of the patient group with ≥5 years for long duration and ≥24 years of age for late disease onset. ACC: anterior cingulate cortex; AmyL: left amygdala; PrC: precuneus; SGC: subgenual cingulate cortex.